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ABSTRACT
Introduction: Squamous carcinoma is the commonest malignancy of the head and neck region. It is associated with high 
morbidity and mortality. Epidermal growth factor receptor (EGFR) regulates downstream signaling pathways through 
its tyrosine kinase (TK) domains that play a role in cell proliferation and survival. EGFR mutations have been found to 
occur between exons 18 to 21 on chromosome 7. Limited studies are available on EGFR-TK mutations in the head and 
neck squamous cell carcinoma (HNSCC) globally. This study explores EGFR mutations in 30 HNSCC cases presenting to 
a tertiary care hospital over a period of two years. Material and Methods: Fresh tumor tissue was collected from the 
resection specimens of cases of primary HNSCC. Cases with pre-operative therapy were not included. Parameters in 
the form of patients’ age, gender, smoking/tobacco intake, site of the lesion were recorded. Tumor parameters after 
histopathological examination were recorded in the form of TNM stage, tumor grade. DNA was extracted from fresh 
tissue of all the cases. EGFR Mutation Analysis Kit assay was used to detect mutations of the EGFR gene. PCR was run and 
results were analyzed. Results: EGFR Mutations were found in 6.7%of the patients. There was no significant association 
of the EGFR Mutation with the studied parameters.  Conclusion: EGFR mutations are present in a subset of patients of 
HNSCC. Patients having these mutations may benefit from targeted therapy with tyrosine kinase inhibitors. 
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INTRODUCTION
Squamous cell carcinoma is the most common 
malignancy of the head and neck region.1 It is 
associated with high morbidity, and mortality.2 Recent 
genomic studies showed a molecular heterogeneity 
associated with this entity, which involves multiple 
carcinogenesis pathways.3 Various risk factors play 
a role in developing head and neck squamous cell 
carcinoma (HNSCC) like tobacco, alcohol, and 
virus such as human papillomavirus (HPV).4,5 Self-
sufficiency of growth signals is one of the hallmarks 
of carcinogenesis. The epidermal growth factor 
receptor (EGFR), a receptor for the epidermal growth 
factor (EGF), is composed of transmembrane and 
cytoplasmic tyrosine kinase domain, which controls 
downstream signaling pathways that play a role in 
the cell division and survival. Downstream signaling 
pathways like Mitogen-Activated Protein Kinase 
(MAPK), phosphatidylinositol-3- kinase (PI3K)-AKT, and 
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Signal Transducer and Activator of Transcription (STAT) 
are responsible for various steps in carcinogenesis like 
cell division, cell migration, and angiogenesis.6 The 
EGFR Tyrosine Kinase (TK) domain mutations have been 
found to occur on chromosome 7 from the exon 18 to 
21. These comprise of a single base deletion, insertions, 
or substitutions. EGFR mutations have been studied in 
solid organ tumors like non-small cell lung carcinoma. 
Patients having these mutations have shown good 
response to targeted therapy with EGFR-tyrosine kinase 
inhibitors (TKIs) like Gefitinib.7,8
Studies on EGFR mutations in cases of HNSCC are 
limited. Therefore, a study of the presence of mutations 
in EGFR-TK in our population may improve therapies 
for these patients. This study explores the presence 
of mutations in the EGFR-TK gene on chromosome 
7 between exons 18 to 21 in 30 HNSCC patients 
presenting to a tertiary care hospital for two years.
MATERIAL AND METHODS
A cross-sectional descriptive study was done to 
study EGFR mutations in squamous cell carcinoma 
of the head and neck (HNSCC), to evaluate EGFR 
mutations in cases of HNSCC and correlate EGFR 
mutations with the various patient and tumor 
parameters in a tertiary care hospital.
Institutional ethics committee clearance was 
obtained prior to proceeding with the study. The study 
was carried out on all cases of biopsy-proven squamous 
cell carcinomas of the head and neck, presenting to a 
tertiary care hospital over two years.
All consecutive cases of Head and Neck region 
diagnosed as squamous cell carcinoma (HNSCC), and 
in which resection specimens of the primary tumor 
was received at the Department of Pathology, tertiary 
care hospital, starting from Jan 2016 up to Dec 2017 
were compiled.
The cases that  rece ived,  preoperat ive ly , 
radiotherapy, and/or chemotherapy were excluded 
from the study. Secondary metastatic tumors to the 
head and neck were not included.
The minimum number of patients in our study 
to achieve statistical significance was calculated and 
found out to be 30.
Fresh HNSCC tissue was collected from the 
resection specimens of 33 cases (Jan 2016- Dec 2017). 
The tissue was stored in saline at -40 Celsius degrees. 
Parameters in the form of patients’ age, gender, 
smoking/tobacco intake, duration of symptoms, and 
the lesion site were recorded. After histopathological 
examination, tumor parameters were recorded in 
the form of the TNM stage as per AJCC 7th edition, 
Grade of the tumor as per Broders’s criteria into well, 
moderately, and poorly-differentiated, lymphovascular 
invasion, perineural invasion, and extra-nodal tumor 
extension.
DNA was extracted from fresh tissue of all the 
cases and the quality was assessed by nanodrop 
spectrometry. Three samples had to be rejected due 
to the suboptimal quality of DNA. Mutational analysis 
was done on the remaining 30 samples.
Genomic DNA was isolated using the Pure Link 
Genomic DNA Kit by the kit protocol and quantified 
using the nanodrop.
DNA concentration of greater than 10 ng/
microliter and A 260/280 ratio greater than 1.8 was 
considered adequate. (A 260/280 ratio less than 1.8 
indicated more protein content). This assay required 
approximately 80 ng of DNA for each sample per run 
(10 ng/reaction). Lower concentrations were adjusted 
with the water volume during the reaction setup.
The EGFR Mutation Analysis Kit (EGFR Mutation 
Analysis Kit Instructions for use For In Vitro Diagnostic 
Use EntroGen, Inc. 7) assay was used to detect 
mutations in exons 18, 19, 20, and 21 of the EGFR.
The mutations detected in each reaction were:
• p.T790M (Exon 20);
• Exon 19 Deletions - detects 19 deletions, but did not 
distinguish between them;
• p.L858R (Exon 21);
• p.L861Q (Exon 21);
• p.S768I (Exon 20);
• p.G719* (Exon 18) - detects G719A, G719S, and 
G719C, but did not distinguish between them;
• Exon 20 Insertions - detects c.2319_2320 ins CAC and 
c.2310-2311 ins GGT, but did not distinguish between 
them;
• Exon 20 Insertion - detects c. 2307_2308 ins9 
GCCAGCGTG.
The endogenous control primers were run to 
amplify an unrelated gene used to determine the 
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condition of reagents and whether the reaction 
contains a sufficient amount of amplifiable DNA.
The regents were prepared as per the kit 
instructions, and the PCR reactions were set up in a 
total volume of 30microlitre/sample.
The PCR was run on Roche Light Cycler R 480 
(Software version 1.5), and results were analyzed.
RESULTS
The mean age of the patients was 58.2 years 
(Figure 1). There was a male preponderance (83.3%).
The most common site of the tumor was the 
tongue (33.3%), followed by the buccal mucosa 
(20%), mandible (10%), and maxilla (6.7%). One case 
was found on the floor of the mouth, gingivobuccal 
sulcus, glottis, larynx, lip, oropharynx, supra-glottis, 
tonsillar fossa, and tonsillar pillar.
50% of the patients chewed tobacco, while 
26.7% were smokers. The TNM stage was (i) T1 in 11 
cases (36.7%), (ii) T2 in X cases (13.3%), (iii) T3 in 3 
(10%) patients, and (iv) T4 in 11 (36.7%) patients. The 
majority of the patients (76.7%) had Grade 1 tumors, 
while 5 (16.7%) and 2 (6.7%) patients had Grade 2 
and Grade 3 tumors, respectively.
In our sample, 1 (3.3%) patient presented 
lymphovascular invasion, perineural invasion (PNI) was 
found in 1 (3.3%) patient, and extranodal extension 
was observed in 2 (6.7%) patients.
EGFR mutations were found in 2 (6.7%) patients. 
One patient had a single mutation (p.S768I), while the 
other patient had two mutations (p.S768I, p.T790M).
It was observed that both the EGFR mutations 
were located in the exon 20.
Both the patients with EGFR mutation were in the 
age group of 51-60 years. Both the EGFR mutations 
were positive in the tumor of the tongue as the primary 
site.
Data were analyzed using appropriate statistical 
tests in unpaired t-test, Fisher test, student t-test, and 
chi-square test.
There was no significant association between 
EGFR mutations with age, gender, or history of tobacco 
intake. There was no significant association of EGFR 
mutation and stage or grade of the tumor (Tables 1-5).
DISCUSSION
EGFR became one of the commonly investigated 
targets for new therapies in solid organ tumors. 
However, limited studies have been done on these 
mutations in cases of HNSCC globally.
In 2017, Christos Perisanidis9 undertook a 
systematic review of EGFR mutations in HNSCC, 
comparing the statistics of EGFR mutations worldwide. 
The EGFR polymorphic variation in HNSCC was found 
to be specific to geographic regions and ethnicity with 
varying prevalence in different populations. Among the 
four Continents, Southeast Asia (4.9%), followed by 
North America (2.7%), showed the highest prevalence. 
When considering individual countries, the highest 
prevalence of 15.1% was found in the Republic of 
Korea, followed by the Czech Republic (6.9%). In our 
study, the incidence of EGFR mutations was 6.6% 
(2/30 cases), which is comparable with the study by 
Smilek et al.10 6.9% (2/29 cases). Our study found that 
both mutations were found in tumors arising from 
the tongue. This is consistent with other studies by 
Smilek et al.10,  Nagalakshmi et al.,11 and the systemic 
review by Perisanidis et al.9.
Our study failed to show any correlation of 
the presence of these mutations with age, gender, 
smoking, stage, or grade of the tumor, which is 
consistent with the prospective clinical study of EGFR 
mutations by Smilek et al.10 The Smilek study comprised 
29 cases of HNSCC and detected two cases (stage III 
and IV) with the EGFR mutation. The EGFR mutation 
with a deletion in exon 19 was associated with a worse 
prognosis, presence of recurrence, and no response 
to treatment.
Nagalakshmi et al.,11 in a hospital-based case-
control study, reported a significant association of 
EGFR mutations with an advanced stage of HNSCC, Figure 1. Distribution of patients according to Age
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N % N % N %
31-40 0 - 1 3.3% 1 3.3%
>0.05
41-50 0 - 3 10% 3 10%
51-60 2 6.7% 12 40% 14 46.7%
61-70 0 - 11 36.7% 11 36.7%
71-80 0 - 1 3.3% 1 3.3%
Total 2 6.7% 28 93.3% 30 100%
Mean ± SD 53.5 ± 2.12 58.6 ± 8.57 58.2 ± 8.38
N= Number of patients having EGFR mutation. SD= Standard Deviation. p Value= Probability Value.





N % N % N %
Male 1 3.3% 4 13.3% 5 16.7%
>0.05Female 1 3.3% 24 80% 25 83.3%
Total 2 6.7% 28 93.3% 30 100%
N= Number of patients having EGFR mutation. SD= Standard Deviation. p Value= Probability Value.





N % N % N %
Tobacco chewing 1 3.3% 14 46.7% 15 50%
>0.05
Tobacco smoking 0 - 8 26.7% 8 26.7%
Smoking and chewing tobacco 0 - 1 3.3% 1 3.3%
No smoking/chewing tobacco 1 3.3% 5 16.7% 6 20%
Total 2 6.7% 28 93.3% 30 100%
N= Number of patients having EGFR mutation. SD= Standard Deviation. p Value= Probability Value.





N % N % N %
0 0 - 1 3.3% 1 3.3%
>0.05
1 0 - 11 36.7% 11 36.7%
2 1 3.3% 3 10% 4 13.3%
3 0 - 3 10% 3 10%
4 1 3.3% 10 33.4% 11 36.7%
Total 2 6.7% 28 93.3% 30 100%
N= Number of patients having EGFR mutation. SD= Standard Deviation. p Value= Probability Value.
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history of tobacco/alcohol, and age more than 
49 years. Bahassi et al.12 reported a case with mutated 
EFGR, which presented a positive impact on treatment.
The comparison of the results of our study with 
other studies is depicted in Table 6.
The variation in EGFR mutations results may be 
attributed to various detection methods used to study 
these mutations, which present varied sensitivity and 
specificity.
In the study by Nagalakshmi et al . ,11 the 
single strand confirmatory polymorphism was 
the molecular technique used along with Sanger 
Sequencing, hence enabling detection of a large 
number of mutations. The study by Smilek et al.10 
and the present study, on the other hand, were 
done to study specific mutations that have a role in 
targeted therapy using primer and probes by PCR 
technology.
Table 6. Comparison of our study results with two other studies on EGFR mutation in HNSCC
Parameters Current Study Smilek et al.10 Nakalakshmi et al.11
Total cases 30 29 129
Males 25 24 65
Females 05 05 64
Age
> or=50 years 21 15 89
< 50 years 9 14 40
Country India Czech Republic India
Tumor site
Oral cavity 26 02 36
Oropharynx 01 19 16
Hypopharynx 0 05 00
Larynx 03 03 06
TNM Stage
Stage I 11 0 7
Stage II 04 0 9
Stage III 03 05 17
Stage IV 12 24 32
Tumor Grade
Grade 1 23 03 40
Grade 2 05 17 17
Grade 3 02 09 08
EGFR mutation 02/30 6% 02/29 6% 81.39%
Samples FTT FTT FTT
Method PCR PCR PCR and SSCP
Mutation p.S768I, p.T790M on Exon 20 Exon 19 del
Exon 18, 19, 20 
mutations
FTT= fresh tumor tissue; SSCP= single strand confirmatory polymorphism





N % N % N %
1 2 6.7% 21 70% 23 76.7%
>0.05
2 0 - 5 16.7% 5 16.7%
3 0 - 2 6.7% 2 6.7%
Total 2 6.7% 28 93.3% 30 100%
N= Number of patients having EGFR mutation. SD= Standard Deviation. p Value= Probability Value.
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CONCLUSION
HNSCC is one of the commonest malignancies 
in India and has an aggressive course. Mutations 
in the tyrosine kinase domain of the EGFR gene 
on Exons 19 to 21 is one of the multiple molecular 
pathways of tumorigenesis in head and neck squamous 
cell carcinoma. Studies have shown that EGFR TK 
mutations are present in a subset of these tumors. TKI 
therapy may have a role in the treatment of patients 
harboring these mutations. However, the challenge 
is finding out the specific EGFR mutations related to 
resistance or response to anti-EGFR or other targeted 
therapies. Larger studies and clinical trials may help 
provide targeted therapy to a subset of patients found 
with EGFR TKI mutations.
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